CDC 4370/ Bangkok TFV Study

Status:Completed
Phase:III, II
Principal Investigator(s):Kachit Choopanya, MD
Objective:To assess the safety and efficacy of daily tenofovir to prevent parenteral HIV infection among injection drug users (IDU) in Thailand. IDU was defined as individuals who reported substance use in the past year from the time they were screened.Key results: There was a 49% reduction in HIV infection rate among IDU in Thailand with Daily oral TDF. Last update August 10, 2022
Prevention Option(s):PrEP
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionDaily dosing
Mode of DeliveryTablet
ARMsExperimental
Results: [June 2013] Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand
Official Code: NCT00119106
Related Publications:
Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand.
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial
Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study
The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs
Risk behaviors and risk factors for HIV infection among participants in the Bangkok tenofovir study, an HIV pre-exposure prophylaxis trial among people who inject drugs
Trial Sponsors: Bangkok Metropolitan Administration Medical College and Vajira Hospital, Thailand Ministry of Health, US CDC
Start Date
End Date
June 30, 2005
October 1, 2014
Enrollment:2,413
Age range: 20 Years ↔ 60 Years
Population:Injecting drug users